Download PDF
Z Gastroenterol 2020; 58(12): 1233-1240
DOI: 10.1055/a-1291-8483
Übersicht

Leberspezifische Diagnostik bei der nichtalkoholischen Fettlebererkrankung (NAFLD) – wann kann die Leberbiopsie ersetzt werden?

Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) – time to replace liver biopsy?
Maurice Michel 
  Schwerpunkt für Metabolische Lebererkrankungen, I. Medizinische Klinik, Universitätsmedizin Mainz, Mainz, Deutschland
,
Jörn M. Schattenberg 
  Schwerpunkt für Metabolische Lebererkrankungen, I. Medizinische Klinik, Universitätsmedizin Mainz, Mainz, Deutschland
› Author AffiliationsSupported by: JMS erhält Forschungsförderung der Europäischen Union Innovative Medicines Initiative 2 (IMI2) (Grant Nummer 777377: LITMUS – Liver Investigation: Testing Biomarker Utility in Steatohepatitis).
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die nichtalkoholische Fettlebererkrankung (NAFLD) ist eine der häufigsten Lebererkrankungen. In Deutschland wird die Prävalenz in der adulten Bevölkerung auf 24 % geschätzt, und die Inzidenz ist ansteigend. Prognostisch ist die Unterscheidung früher und fortgeschrittener Erkrankungsstadien von Bedeutung. Insbesondere das Ausmaß der Vernarbung, die als Leberfibrose bezeichnet wird, beeinflusst Morbidität und Mortalität von Patienten mit NAFLD. Bei Vorliegen einer fortgeschrittener Fibrose und Zirrhose steigen die leberspezifische und die Gesamtmortalität an. Die Leberfibrose entsteht als Konsequenz einer anhaltenden Entzündung des Lebergewebes über die Zeit. Da Entzündung und Fibrose histologische Merkmale der Erkrankung sind, gilt heute als Referenzmethode in der Diagnostik der NAFLD noch die Leberbiopsie. Zunehmend werden nichtinvasive diagnostische Verfahren zum Staging (der Fibrose) und Grading (Aktivität) der Erkrankung entwickelt und validiert. Die aktuelle Übersicht fasst neue Entwicklungen der nichtinvasiven Leberdiagnostik zusammen.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. In Germany, the prevalence in the adult population is estimated at 24 % and the incidence is increasing. Prognostically, the distinction between early and advanced stages of the disease is important. In particular, the extent of scarring considered as liver fibrosis is of prognostic significance. Patients with advanced fibrosis and cirrhosis show increased mortality. Liver fibrosis develops as a consequence of a persistent inflammation of the liver tissue over time. Since inflammation and fibrosis are histological features, liver biopsy is considered the reference method in the diagnosis of NAFLD. More recently, non-invasive diagnostic methods for staging (of fibrosis) and grading (activity) of the disease are being developed and validated. The current review summarizes new developments in non-invasive liver diagnostics.

Schlüsselwörter

NAFLD - NASH - Fibrosemarker - Leberbiopsie - transiente Elastografie

Key words

NAFLD - NASH - fibrosis marker - liver biopsy - transient elastography


Publication History

Received: 31 July 2020

Accepted: 09 October 2020

Article published online:
08 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Younossi ZM, Koenig AB, Abdelatif D. et al Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84 . doi:10.1002/hep.28431
    CrossrefPubMedGoogle Scholar
  • 2 Wong RJ, Singal AK. Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014–2019. JAMA Netw Open 2020; 3: e1920294 . doi:10.1001/jamanetworkopen.2019.20294
    CrossrefPubMedGoogle Scholar
  • 3 Roeb E, Steffen HM, Bantel H. et al S2k-Leitlinie nicht alkoholische Fettlebererkrankungen. Z Gastroenterol 2015; 53: 668-723 . doi:10.1055/s-0035-1553193
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Eslam M, Newsome PN, Sarin SK. et al A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020; DOI: 10.1016/j.jhep.2020.03.039.
    CrossrefPubMedGoogle Scholar
  • 5 Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med 2017; 377: 2063-2072 . doi:10.1056/NEJMra1503519
    CrossrefPubMedGoogle Scholar
  • 6 Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int 2013; 7 (Suppl. 02) 765-770 . doi:10.1007/s12072-013-9446-z
    CrossrefPubMedGoogle Scholar
  • 7 Michel M, Kalliga E, Labenz C. et al Ein junger Patient mit Typ-2-Diabetes assoziierter nichtalkoholischer Steatohepatitis, Leberzirrhose und hepatozellulärem Karzinom. Z Gastroenterol 2020; 58: 57-62 . doi:10.1055/a-1062-8788
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Angulo P, Kleiner DE, Dam-Larsen S. et al Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149: 389-397.e10 . doi:10.1053/j.gastro.2015.04.043
    CrossrefPubMedGoogle Scholar
  • 9 Taylor RS, Taylor RJ, Bayliss S. et al Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. Gastroenterology 2020; DOI: 10.1053/j.gastro.2020.01.043.
    CrossrefPubMedGoogle Scholar
  • 10 Labenz C, Huber Y, Michel M. et al Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Dig Dis Sci 2019; DOI: 10.1007/s10620-019-05986-9.
    CrossrefPubMedGoogle Scholar
  • 11 Labenz C, Huber Y, Michel M. et al Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatol Commun 2020; DOI: 10.1002/hep4.1541.
    CrossrefPubMedGoogle Scholar
  • 12 Huber Y, Labenz C, Michel M. et al The Incidence of cancer in patients living with non-alcoholic fatty liver disease (NAFLD) in Germany. Dtsch Arztebl Int 2020; Accepted Article
    PubMedGoogle Scholar
  • 13 Kaps L, Labenz C, Galle PR. et al Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J 2020; DOI: 10.1177/2050640620944098.
    CrossrefPubMedGoogle Scholar
  • 14 Gehrke N, Schattenberg JM. Metabolic inflammation – a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)?. Gastroenterology 2020; DOI: 10.1053/j.gastro.2020.02.020.
    CrossrefPubMedGoogle Scholar
  • 15 Cook N, Geier A, Schmid A. et al Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis. JHEP Reports 2020; 2: 100081 . doi:10.1016/j.jhepr.2020.100081
    CrossrefPubMedGoogle Scholar
  • 16 Davison BA, Harrison SA, Cotter G. et al Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. Journal of Hepatology 2020; DOI: 10.1016/j.jhep.2020.06.025.
    CrossrefPubMedGoogle Scholar
  • 17 Schattenberg JM, Straub BK. On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. Journal of Hepatology 2020; DOI: 10.1016/j.jhep.2020.07.020.
    CrossrefPubMedGoogle Scholar
  • 18 European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 . doi:10.1016/j.jhep.2015.11.004
    CrossrefPubMedGoogle Scholar
  • 19 Kleiner DE, Brunt EM, van Natta M. et al Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 . doi:10.1002/hep.20701
    CrossrefPubMedGoogle Scholar
  • 20 Schattenberg JM, Straub BK. Differenzialdiagnose der Fettlebererkrankung. Gastroenterologe 2020; 69: 896 . doi:10.1007/s11377-020-00416-z
    PubMedGoogle Scholar
  • 21 Ratziu V, Charlotte F, Heurtier A. et al Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906 . doi:10.1053/j.gastro.2005.03.084
    CrossrefPubMedGoogle Scholar
  • 22 Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500 . doi:10.1056/NEJM200102153440706
    CrossrefPubMedGoogle Scholar
  • 23 Geier A, Boursier J. Non-invasive diagnosis of patients with ‘at-risk’ NAFLD: only fibrosis counts?. Gut 2020; 69: 1164-1165 . doi:10.1136/gutjnl-2020-320785
    CrossrefPubMedGoogle Scholar
  • 24 Hernaez R, Lazo M, Bonekamp S. et al Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090 . doi:10.1002/hep.24452
    CrossrefPubMedGoogle Scholar
  • 25 Petta S, Maida M, Macaluso FS. et al The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 2015; 62: 1101-1110 . doi:10.1002/hep.27844
    CrossrefPubMedGoogle Scholar
  • 26 Tapper EB, Challies T, Nasser I. et al The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2016; 111: 677-684 . doi:10.1038/ajg.2016.49
    CrossrefPubMedGoogle Scholar
  • 27 Wong VWS, Vergniol J, Wong GLH. et al Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462 . doi:10.1002/hep.23312
    CrossrefPubMedGoogle Scholar
  • 28 Kennedy P, Wagner M, Castéra L. et al Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018; 286: 738-763 . doi:10.1148/radiol.2018170601
    CrossrefPubMedGoogle Scholar
  • 29 Sugimoto K, Moriyasu F, Oshiro H. et al The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis. Radiology 2020; 192665 DOI: 10.1148/radiol.2020192665.
    CrossrefPubMedGoogle Scholar
  • 30 Jiang W, Huang S, Teng H. et al Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 2018; 8: e021787 . doi:10.1136/bmjopen-2018-021787
    CrossrefPubMedGoogle Scholar
  • 31 Palmeri ML, Wang MH, Rouze NC. et al Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. Journal of Hepatology 2011; 55: 666-672 . doi:10.1016/j.jhep.2010.12.019
    CrossrefPubMedGoogle Scholar
  • 32 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Reports 2020; 2: 100067 . doi:10.1016/j.jhepr.2020.100067
    CrossrefPubMedGoogle Scholar
  • 33 Serra-Burriel M, Graupera I, Torán P. et al Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol 2019; 71: 1141-1151 . doi:10.1016/j.jhep.2019.08.019
    CrossrefPubMedGoogle Scholar
  • 34 Ratziu V, Cadranel JF, Serfaty L. et al A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol 2012; 57: 376-383 . doi:10.1016/j.jhep.2012.03.019
    CrossrefPubMedGoogle Scholar
  • 35 Permutt Z, Le TA, Peterson MR. et al Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-29 . doi:10.1111/j.1365-2036.2012.05121.x
    CrossrefPubMedGoogle Scholar
  • 36 Roeb E, Geier A. Nichtalkoholische Steatohepatitis (NASH) – aktuelle Behandlungsempfehlungen und zukünftige Entwicklungen. Z Gastroenterol 2019; 57: 508-517 . doi:10.1055/a-0784-8827
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Bohte AE, van Werven JR, Bipat S. et al The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011; 21: 87-97 . doi:10.1007/s00330-010-1905-5
    CrossrefPubMedGoogle Scholar
  • 38 Angulo P, Hui JM, Marchesini G. et al The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 . doi:10.1002/hep.21496
    CrossrefPubMedGoogle Scholar
  • 39 Sterling RK, Lissen E, Clumeck N. et al Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325 . doi:10.1002/hep.21178
    CrossrefPubMedGoogle Scholar
  • 40 McPherson S, Stewart SF, Henderson E. et al Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269 . doi:10.1136/gut.2010.216077
    CrossrefPubMedGoogle Scholar
  • 41 Younes R, Rosso C, Blanco MJG. et al PS-205-Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients. J Hepatol 2019; 70: e136-e137 . doi:10.1016/S0618-8278(19)30239-7
    CrossrefPubMedGoogle Scholar
  • 42 Lazarus JV, Colombo M, Cortez-Pinto H. et al NAFLD – sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol 2020; 17: 377-379 . doi:10.1038/s41575-020-0315-7
    CrossrefPubMedGoogle Scholar
  • 43 Karsdal MA, Daniels SJ, Holm Nielsen S. et al Collagen biology and non-invasive biomarkers of liver fibrosis. Liver International 2020; 40: 736-750 . doi:10.1111/liv.14390
    CrossrefPubMedGoogle Scholar
  • 44 Daniels SJ, Leeming DJ, Eslam M. et al ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology 2019; 69: 1075-1086 . doi:10.1002/hep.30163
    CrossrefPubMedGoogle Scholar
  • 45 Boyle M, Tiniakos D, Schattenberg JM. et al Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports 2019; 1: 188-198 . doi:10.1016/j.jhepr.2019.06.004
    PubMedGoogle Scholar
  • 46 Vali Y, Lee J, Boursier J. et al Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020; DOI: 10.1016/j.jhep.2020.03.036.
    CrossrefPubMedGoogle Scholar
  • 47 Verma S, Jensen D, Hart J. et al Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver International 2013; 33: 1398-1405 . doi:10.1111/liv.12226
    CrossrefPubMedGoogle Scholar
  • 48 Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-199 . doi:10.1016/S0168-8278(01)00094-0
    CrossrefPubMedGoogle Scholar
  • 49 Jun BG, Park WY, Park EJ. et al A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis. PLoS ONE 2017; 12: e0182784 . doi:10.1371/journal.pone.0182784
    CrossrefPubMedGoogle Scholar
  • 50 Eddowes PJ, Sasso M, Allison M. et al Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156: 1717-1730 . doi:10.1053/j.gastro.2019.01.042
    CrossrefPubMedGoogle Scholar
  • 51 Byun J, Lee SS, Sung YS. et al CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard. Eur Radiol 2019; 29: 4427-4435 . doi:10.1007/s00330-018-5905-1
    CrossrefPubMedGoogle Scholar
  • 52 Younossi ZM, Loomba R, Anstee QM. et al Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68: 349-360 . doi:10.1002/hep.29721
    CrossrefPubMedGoogle Scholar
  • 53 Guha IN, Parkes J, Roderick P. et al Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460 . doi:10.1002/hep.21984
    CrossrefPubMedGoogle Scholar
  • 54 Musso G, Gambino R, Cassader M. et al Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 . doi:10.3109/07853890.2010.518623
    CrossrefPubMedGoogle Scholar
  • 55 Yoneda M, Fujii H, Sumida Y. et al Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 1300-1306 . doi:10.1007/s00535-011-0436-4
    CrossrefPubMedGoogle Scholar
  • 56 Suzuki A, Lymp J, St SauverJ. et al Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 2006; 26: 1209-1216 . doi:10.1111/j.1478-3231.2006.01362.x
    CrossrefPubMedGoogle Scholar